NNC 112

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584825

CAS#: 125341-24-4

Description: NNC 112 is a selective dopamine D1 receptor antagonists.


Chemical Structure

img
NNC 112
CAS# 125341-24-4

Theoretical Analysis

MedKoo Cat#: 584825
Name: NNC 112
CAS#: 125341-24-4
Chemical Formula: C19H18ClNO2
Exact Mass: 327.10
Molecular Weight: 327.808
Elemental Analysis: C, 69.62; H, 5.53; Cl, 10.81; N, 4.27; O, 9.76

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: NNC 112; NNC-112; NNC112; NO-112

IUPAC/Chemical Name: 1H-3-Benzazepin-7-ol, 5-(7-benzofuranyl)-8-chloro-2,3,4,5-tetrahydro-3-methyl-, (S)-

InChi Key: RUSANBIFMAXXSJ-MRXNPFEDSA-N

InChi Code: InChI=1S/C19H18ClNO2/c1-21-7-5-13-9-17(20)18(22)10-15(13)16(11-21)14-4-2-3-12-6-8-23-19(12)14/h2-4,6,8-10,16,22H,5,7,11H2,1H3/t16-/m1/s1

SMILES Code: OC1=C(Cl)C=C2CCN(C)C[C@H](C3=C(OC=C4)C4=CC=C3)C2=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 327.81 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Andersen PH, Grønvald FC, Hohlweg R, Hansen LB, Guddal E, Braestrup C, Nielsen EB. NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists. Eur J Pharmacol. 1992 Aug 14;219(1):45-52. PubMed PMID: 1397049.

2: Nielsen EB, Andersen PH. Dopamine receptor occupancy in vivo: behavioral correlates using NNC-112, NNC-687 and NNC-756, new selective dopamine D1 receptor antagonists. Eur J Pharmacol. 1992 Aug 14;219(1):35-44. PubMed PMID: 1397048.

3: Halldin C, Foged C, Chou YH, Karlsson P, Swahn CG, Sandell J, Sedvall G, Farde L. Carbon-11-NNC 112: a radioligand for PET examination of striatal and neocortical D1-dopamine receptors. J Nucl Med. 1998 Dec;39(12):2061-8. PubMed PMID: 9867142.

4: Ekelund J, Slifstein M, Narendran R, Guillin O, Belani H, Guo NN, Hwang Y, Hwang DR, Abi-Dargham A, Laruelle M. In vivo DA D(1) receptor selectivity of NNC 112 and SCH 23390. Mol Imaging Biol. 2007 May-Jun;9(3):117-25. PubMed PMID: 17473957.

5: Granda ML, Schroeder FA, Borra RH, Schauer N, Aisaborhale E, Guimaraes AR, Hooker JM. First D1-like receptor PET imaging of the rat and primate kidney: implications for human disease monitoring. Am J Physiol Renal Physiol. 2014 Jul 1;307(1):F116-21. doi: 10.1152/ajprenal.00111.2014. Epub 2014 May 7. PubMed PMID: 24808534; PubMed Central PMCID: PMC4347741.

6: Kim SW, Fowler JS, Skolnick P, Muench L, Kang Y, Shea C, Logan J, Kim D, Carter P, King P, Alexoff D, Volkow ND. Therapeutic doses of buspirone block D3 receptors in the living primate brain. Int J Neuropsychopharmacol. 2014 Aug;17(8):1257-67. doi: 10.1017/S1461145714000194. Epub 2014 Mar 28. Erratum in: Int J Neuropsychopharmacol. 2014 Aug;17(8):1354. PubMed PMID: 24679922.

7: Cannon DM, Klaver JM, Peck SA, Rallis-Voak D, Erickson K, Drevets WC. Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [11C]NNC-112. Neuropsychopharmacology. 2009 Apr;34(5):1277-87. doi: 10.1038/npp.2008.194. Epub 2008 Oct 22. PubMed PMID: 18946469; PubMed Central PMCID: PMC2656589.

8: Cropley VL, Fujita M, Bara-Jimenez W, Brown AK, Zhang XY, Sangare J, Herscovitch P, Pike VW, Hallett M, Nathan PJ, Innis RB. Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA. Psychiatry Res. 2008 Jul 15;163(2):171-82. doi: 10.1016/j.pscychresns.2007.11.003. Epub 2008 May 27. PubMed PMID: 18504119.

9: Abi-Dargham A, Martinez D, Mawlawi O, Simpson N, Hwang DR, Slifstein M, Anjilvel S, Pidcock J, Guo NN, Lombardo I, Mann JJ, Van Heertum R, Foged C, Halldin C, Laruelle M. Measurement of striatal and extrastriatal dopamine D1 receptor binding potential with [11C]NNC 112 in humans: validation and reproducibility. J Cereb Blood Flow Metab. 2000 Feb;20(2):225-43. PubMed PMID: 10698059.

10: Slifstein M, Kegeles LS, Gonzales R, Frankle WG, Xu X, Laruelle M, Abi-Dargham A. [11C]NNC 112 selectivity for dopamine D1 and serotonin 5-HT(2A) receptors: a PET study in healthy human subjects. J Cereb Blood Flow Metab. 2007 Oct;27(10):1733-41. Epub 2007 Feb 21. PubMed PMID: 17311076.

11: Robertson CL, Ishibashi K, Mandelkern MA, Brown AK, Ghahremani DG, Sabb F, Bilder R, Cannon T, Borg J, London ED. Striatal D1- and D2-type dopamine receptors are linked to motor response inhibition in human subjects. J Neurosci. 2015 Apr 15;35(15):5990-7. doi: 10.1523/JNEUROSCI.4850-14.2015. PubMed PMID: 25878272; PubMed Central PMCID: PMC4397600.

12: Karimi M, Moerlein SM, Videen TO, Su Y, Flores HP, Perlmutter JS. Striatal dopamine D1-like receptor binding is unchanged in primary focal dystonia. Mov Disord. 2013 Dec;28(14):2002-6. doi: 10.1002/mds.25720. Epub 2013 Oct 21. PubMed PMID: 24151192; PubMed Central PMCID: PMC4086787.

13: Finnema SJ, Bang-Andersen B, Jørgensen M, Christoffersen CT, Gulyás B, Wikström HV, Farde L, Halldin C. The dopamine D₁ receptor agonist (S)-[¹¹C]N-methyl-NNC 01-0259 is not sensitive to changes in dopamine concentration--a positron emission tomography examination in the monkey brain. Synapse. 2013 Sep;67(9):586-95. doi: 10.1002/syn.21664. Epub 2013 Apr 18. PubMed PMID: 23504964.

14: Slifstein M, Kolachana B, Simpson EH, Tabares P, Cheng B, Duvall M, Frankle WG, Weinberger DR, Laruelle M, Abi-Dargham A. COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET. Mol Psychiatry. 2008 Aug;13(8):821-7. doi: 10.1038/mp.2008.19. Epub 2008 Mar 4. PubMed PMID: 18317466.

15: Guo N, Hwang DR, Lo ES, Huang YY, Laruelle M, Abi-Dargham A. Dopamine depletion and in vivo binding of PET D1 receptor radioligands: implications for imaging studies in schizophrenia. Neuropsychopharmacology. 2003 Sep;28(9):1703-11. Epub 2003 Jun 18. PubMed PMID: 12813475.

16: Narendran R, Frankle WG, Keefe R, Gil R, Martinez D, Slifstein M, Kegeles LS, Talbot PS, Huang Y, Hwang DR, Khenissi L, Cooper TB, Laruelle M, Abi-Dargham A. Altered prefrontal dopaminergic function in chronic recreational ketamine users. Am J Psychiatry. 2005 Dec;162(12):2352-9. PubMed PMID: 16330601.

17: Poels EM, Girgis RR, Thompson JL, Slifstein M, Abi-Dargham A. In vivo binding of the dopamine-1 receptor PET tracers [¹¹C]NNC112 and [¹¹C]SCH23390: a comparison study in individuals with schizophrenia. Psychopharmacology (Berl). 2013 Jul;228(1):167-74. doi: 10.1007/s00213-013-3026-8. Epub 2013 Mar 5. PubMed PMID: 23460265.

18: Chou YH, Halldin C, Farde L. Clozapine binds preferentially to cortical D1-like dopamine receptors in the primate brain: a PET study. Psychopharmacology (Berl). 2006 Mar;185(1):29-35. Epub 2006 Jan 5. PubMed PMID: 16395606.

19: Martinez D, Slifstein M, Narendran R, Foltin RW, Broft A, Hwang DR, Perez A, Abi-Dargham A, Fischman MW, Kleber HD, Laruelle M. Dopamine D1 receptors in cocaine dependence measured with PET and the choice to self-administer cocaine. Neuropsychopharmacology. 2009 Jun;34(7):1774-82. doi: 10.1038/npp.2008.235. Epub 2009 Jan 28. PubMed PMID: 19177067; PubMed Central PMCID: PMC2680918.

20: Abi-Dargham A, Xu X, Thompson JL, Gil R, Kegeles LS, Urban N, Narendran R, Hwang DR, Laruelle M, Slifstein M. Increased prefrontal cortical D₁ receptors in drug naive patients with schizophrenia: a PET study with [¹¹C]NNC112. J Psychopharmacol. 2012 Jun;26(6):794-805. doi: 10.1177/0269881111409265. Epub 2011 Jul 18. PubMed PMID: 21768159.